ClotBuster Specialist

What do these conditions have in Common? Heart attacks, Strokes, Athrosclerosis, Thrombophlebitis, Angina, Deep Vein Thrombosis, Ischemia, Cancer, Fibromyalgia, Chronic Fatigue, Lyme Disease, Crohn’s Disease, Diabetes, Gulf War Syndrome, Heavy Metal Toxification, Inflammation, Infections, Vascular Dementia, Intermittent Claudication, Autism-ADD-ADHD, Ulcerative colitis, Hypertension, Spasm, Sinusitis, Laryngitis, Retinopathy, Fibrocystic Breast, ovary, and uterine. Answer: Blood clots, thrombus, and fibrin in large, medium, and small blood vessels virtually anywhere in the body causes or exacerbates the above conditions.

Any inflammation, bacteria, fungus, virus, can trigger blood clotting abnormalities thru excess cross linked fibrin and Fibrinogen circulating through the blood vessels sticking to the walks contributing to formation of excess blood clots and atherosclerosis which slows the blood flow increasing blood viscosity and resulting in increased blood pressure. Blood clots blocks blood flow to muscle, brain, heart, organs, cutting off vital nutrients and oxygen, leading to ischemia such as angina and heart attack or total tissue necrosis and death.

Solution: ClotBuster

A "new, one of a kind" and unique proprietary blend (1. nattokinase, 2. serriopeptidase, 3. lumbrokinase) of natural extracted anti-Fibrinogen & anti-plasminogen enzymes never available before in a single formula. This one of a kind natural formula exhibits a powerful fibrinolytic activity and antiplatelet aggregation factors.

Having the ability to prevent as well as dissolve thrombi from blood vessels and capillaries, ClotBuster goes to work within 1 hour of taking it and lasts 4-6 hours to reestablish and normalize blood circulation. Researchers from Biotechnology Research lab of Japan tested Nattokinase ability to dissolve a thrombus in carotid arteries of rats regained 62% of blood flow. (Enzyme Wave, vol. 3, June 2002)

1. Nattokinase was discovered by Dr. Hiroyuki Sumi M.D. at the blood laboratory of the University of Chicago. It has now over 17 published chemical studies. Dr. Sumi induced blood clots in male dogs and given them 4 capsules of Nattokinase (250mg per capsule) and angiogramed the dogs with Nattokinase which were able to regain normal blood circulation within five hours of oral treatment. (Sumi, H et al JTTAS, 1995)

ClotBuster contains a Standardized Nattokinase of 20.000 FU made from fermented soybean with beneficial bacillus, Natto producing enzymatic peptidases to be absorbed in the intestine duodenum. Therefore, it must be Enteric Coated. Most commercial enzymes in the market are not enteric coated and destroyed by the stomach making it worthless. See published Nattokinase references.

2. Serrapeptase (100.000 unit) is a proteolytic enzyme extracted and purified from the intestine of silk worms. This vitally important enzyme allows the newborn silkworm to dissolve the fibrous cocoon and enzyme after its captivity.

Serrapeptase must be absorbed from the intestines into the bloodstream as an enzyme active form (Moriya N et al, Biotech Appl Biochem Aug 20, 1994).

A clinical study reducing inflammation of breast engorgement in serrapeptase oral patients showed a “marked” improvement of breast pain, breast swelling, and indurations in 85.7% of patients taking serrapeptase with no negative side effects (Kee WH et al. Sing Med. J. Feb 30, 1989)

Another prospective study on post operative swelling and pain of the ankle showed the serrapeptase group 50% decreased swelling by the third day over placebo group (esch PM et al. Fortschr. Med. Feb 10, 1989)

Serrapeptase exceeds in cleaning airway passages by mucolytic effect on sputum viscosity, elasticity, and viscosity of nasal mucus and powerful fibrinolytic, anti-inflammatory, and mucolytic expectorant, and blood vessel anti-inflammatory. See published Serrapeptase references.

3. Lumbrokinase (100.000fu) is a potent fibrinolytic enzyme purified from the digestive track of the earthworm, Lumbricus Rubellus. In China, lumbrokinase won the Science and Technology Advances Award.

The active ingredients in the Earthworm Plasminogen Activator (e-PA) similar to the famous Tissue Plasminogen Activator (t-PA) used would wide to save lives in sudden death and coronary thrombosis in heart attacks. Earthworm Plasminogen Activator (e-PA) can convert plasminogen into plasmin to carry out fibrinolysis and dissolve fibrin from thrombus.

All researched, PubMed search revealed 29 citations. Lumbrokinase is non-toxic, free of negative side effects, and convenient to use showing no abnormal bleeding time and clotting time in vivo studies.

Clinical studies showed oral Lumbrokinase is very effective in ischemic cerebrovascular diseases with an overall therapeutic efficacy of 93.73% and 73.60% showing marked improvement. See published Lumbrokinase references.

ClotBuster
FREQUENTLY ASKED QUESTIONS

1. Any side effects?
ClotBuster is an all natural enzymes of botanical origin with no known side effects. No bleeding or clotting abnormality have been reported. If in case you experience negative side effects, discontinue the product.

2. Can I take ClotBuster after surgery?
There are no known bleeding or clotting side effects, but as a precaution we recommend a waiting period of 5 days after surgery before starting on ClotBuster.

3. Can ClotBuster be taken with blood thinners or antiplatelet aggregation?
ClotBuster does not significantly alter blood tests, such as Prothrombin Time (PT), activated Thromboplastin Time (aPTT), and International Normalized Ratio (INR). Patients should discuss with their Health Practitioner and monitor blood work closely as usual.

4. How should I take ClotBuster?
ClotBuster should be taken on an empty stomach (not eaten for at least 3 hours) and not eat for at least one hour afterwards. Drink water only with ClotBuster.

5. Are there contraindications to ClotBuster?
Yes, if you are allergic to earthworms, Natto soy-fermented beans, or silkworms. You should not take ClotBuster if you are immediately post-surgical, pre-surgical, bleeding, active bleeding ulcer or condition predisposing bleeding events. If you’re taking blood thinners or antiplatelet prescription medication you should read the question above on this subject or consult your Health Practitioners before taking ClotBuster.

Nattokinase Published References
1. Sumi H. Healthy Microbe "Bacillus natto". Japan Bio Science Laboratory Co. Ltd.
2. Fujita M et al (December 1993). "Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan.". Biochemical and Biophysical Research Communications 197 (3): 1340-1347.
3. Sumi H, et al. “A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet.” Experientia 1987, Oct 15;43(10):1110-1.
4. Sumi H, Hamada H, Nakanishi K, Hiratani H. “Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase.” Acta Haematol 1990;84(3):139-43.
5. Sumi H et al (November 2000). "Determination and Properties of the Fibrinolysis Accelerating Substance(FAS) in Japanese Fermented Soybean "Natto".". Nippon Nogeikagaku Kaishi(Japanese). 74 (11): 1259-1264.
6. Prevent Heart Attack and Stroke with Potent Enzyme that Dissolves Deadly Blood Clots in Hours. Health Sciences Institute, March 2002.
7. Maruyama M, Sumi H. Effect of Natto Diet on Blood Pressure. JTTAS, 1995.
8. Pais, E. et al. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35(1-2):139-42.
9. Fujita M, et al (September 1995). "Transport of nattokinase across the rat intestinal tract.". Biological & pharmaceutical bulletin. 18 (9): 1194 - 1196.
10. Fujita, M., Hong, K., et al. “Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat.” Biol Pharm Bull. 1995 Oct;18(10):1387-91.
11. Guyton, A. Function of the Human Body. WB Saunders pp. 83-84.
12. Peng Y, et al. Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo. Appl Microbiol Biotechnol, 69(2): 126-32 2005.
13. Tai MW , Sweet BV Nattokinase for prevention of thrombosis. Am J Health Syst Pharm, 63(12): 1121-3 2006.
14. Cesarone, M.R., et al. Prevention of venous thrombosis in long-haul flights with Flite Tabs: a randomized, controlled trial. Angiology, 54(5): 531-9 2003.
15. Georgios Tsivgoulis, MD; Konstantinos Vemmos, MD; et al. Common Carotid Artery Intima-Media Thickness and the Risk of Stroke Recurrence. Stroke. 2006;37:1913-1916.
16. Suzuki, Y., Kondo, K., Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition, 19(3): 261-4 2003.
17. Suzuki, Y., Kondo, K., et al. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci, 73(10): 1289-98 2003.

Serrapeptase Published References
1. Moriya N,Nakata M, et al. Intestinal absorption of serrapeptase in rats. Biotechnol Appl Biochem. 1994 Aug;20 ( Pt 1):101-8.
2. Guyton, A. Function of the Human Body. WB Saunders pp. 83-84.
3. Malshe PC. “A preliminary trial of serratiopeptidase in patients with carpal tunnel Syndrome.” J Assoc Physicians India, 2000, 48(11):1130.
4. Bracale G,Selvetella L. “Clinical study of the efficacy of and tolerance to seaprose S in inflammatory venous disease. Controlled study versus serratio-peptidase.” Minerva Cardioangiol. 1996 Oct;44(10):515-24.
5. Kee WH,Tan SL,Lee V,Salmon YM. “The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial.” Singapore Med J. 1989 Feb;30(1):48-54.
6. Esch PM,Gerngross H,Fabian A. “Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in treatment with serrapeptase -- a prospective study” Fortschr Med. 1989 Feb 10;107(4):67-8, 71-2.
7. Vicari E,La Vignera S,Battiato C,Arancio A. “Treatment with non-steroidal anti-inflammatory drugs in patients with amicrobial chronic prostato-vesiculitis: transrectal ultrasound and seminal findings.” Minerva Urol Nefrol 2005, 57(1):53-9.
8. Mazzone A,Catalani M,Costanzo M, et al. “Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo”. J Int Med Res. 1990 Sep-Oct;18(5):379-88.
9. Tachibana M,Mizukoshi O, et al. “A multi-centre, double-blind study of Serratiopeptidase versus placebo in post-antrotomy buccal swelling”. Pharmatherapeutica. 1984;3(8):526-30.
10. Nakamura S,Hashimoto Y, et al. “Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease.” Respirology. 2003 Sep;8(3):316-20.
11. Majima Y,Inagaki M. “The effect of an orally administered proteolytic enzyme on the elasticity and viscosity of nasal mucus”. Arch Otorhinolaryngol. 1988;244(6):355-9.
12. Mecikoglu M,Saygi B, et al. “The effect of proteolytic enzyme serratiopeptidase in the treatment of experimental implant-related infection”. J Bone Joint Surg Am. 2006 88(6):1208-14.

Lumbrokinase Published References
1. Fan Q, Wu C, et al. Some features of intestinal absorption of intact fibrinolytic enzyme III-l from Lumbricus rubellus. Biochem Biophys Acta, 2001; 1526(3): 286-92.
2. Gao Y, Qin MZ. Lumbrokinase in treatment of patients with hyperfibrinogenemia of coronary atherogenesis disease. Journal of Capital University of Medical Sciences, 1999; 4(20).
3. Gong B, Wu XY. Observation of using Baiao lumbrokinase capsules to treat ischemic cerebrovascular accident with hyperlipidemia. Capital Medicine, 2000; 7(12): 39.
4. Quo ZF, Liu XX. Observation of treating ischemic cerebrovascular accident with Baiao lumbrokinase capsules. Capital Medicine, 2000; 7(11): 45.
5. Huang ZO, Li ZW, Zhang WX. Lumbrokinase in treating cerebral infarction. Chinese Journal of New Drugs and Clinical Remedies, 2000; 6(19): 453-455.
6. Jie WH. Clinical observation of treating unstable angina in seniors with lumbrokinase. Capital Medicine, 2000; 7(10): 37.
7. Jin L, Jin H, Zhang G, Xu G. Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase. Chinese Journal of Microcirculation, 2000; 23: 213-218.
8. Jing LR, Xu GZ. Dynamics of fibrinolysis and hemostasis in ischemic stroke patients, and the effects of lumbrokinase on those dynamics. Chinese Journal of New Drugs and Clinical Remedies, 1999; 18(1): 48-49.
9. Liao RH. Analytical report of treating 30 patients of ischemic cerebrovascular disease with Panford lumbrokinase and nimodipine. Strait Pharmaceutical Journal, 1997; 9(3): 25-26.
10. Liu J, Zhou LM, Ren Y. Lumbrokinase capsule vs Salvia miltiorrhiza tablet in treating coronary disease with angina pectoris. Chinese Journal of New Drugs and Clinical Remedies, 1999; 1 (18): 17-19.
11. Mihara H, Sumi H, Mizumotoh, et ei. Oral administration of earthworm powder as a possible thrombolytic therapy ed In: Tamkak, Recent advance in thrombosis and fibrinolysis. Hapan Academic Press, 1996, 287.
12. Mihara H, Sumi H, Yoneta T, Mizumoto H, et al. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Jpn J Physiol, 1991; 41: 461-72.
13. Mihara H. A possibility of Earthworm powder as therapeutic agent for thrombosis. Thromb Haemost, 1988; 50: 258.
14. Pan SY. Treating Blood-Stagnation type angina with Baiao lumbrokinase. Capital Medicine, 1998; 9(5):40-41.
15. Pang SQ, Ding MC. Xie SP, et al. A clinical study of therapeutic effectiveness in treating ischemic cerebrovascular disease with Lumbrokinase (Boluoke). Chinese Journal of Neurology and Psychiatry, 1993; 26(4): 229.
16. Park S, Kye KC, Sumi H, et al. Fibrinolytic activity of the earthworm extract. Thromb Haemost, 1989; 62: 545.
17. Park Y, Ryu E, Kim H, Jeong J, et al. Characterization of antithrombotic activity of lumbrokinase-immobilized polyurethane valves in the total artificial heart. Artif Organs,1999; 23: 210-4.
18. Qi W, Yu XB, et al. Effects of lumbrokinase on blood theology of seniors with coronary arterial diseases, Chinese Journal of Microcirculation, 2000; 1(10): 55.
19. Ryu GH, Park S, Kim M, et al. Antighrombogenicity of lumbrokinase-immobilized polyurethane. J Biomed Mater Res, 1994; 28: 1069-77.
20. Tang Y, Liang D, et al. Crystal structure of earthworm fibrinolytic enzyme component a: revealing the structural determinants of its dual fibrinolytic activity. J Mol Biol, 2002; 32(1): 57-68.
21. Wang LH, Yao W. Vermis kinase (Boluoke) therapeutic evaluation to cerebral infarction and influence to blood rheology. Journal of Practical Medical Technology, 1998; 5(2).
22. Wang R, Chen Q, Fang XQ, et al. Effects of Fleroxacin combined with urokinase or earthworm kinase on bacterial biofilm. Acta Pharmaceutica Sinica, 1999; 9(34):662-665.
23. Wang XL, Yan DC. Clinical observation of using Baiao lumbrokinase capsules to treat patients with coronary artery disease secondary to diabetes mellitus. Capital Medicine, 2000; 7(8): 38.
24. Wu XQ, Wu C, et al. Immobilized earthworm fibrinolytic enzyme III-1 with carbonyldiimidazole activated agarose. Protein and Peptide Letters, 2002: 9(1): 75-80.
25. Yang GR. Treating unstable angina with Baiao lumbrokinase capsules. Capital Medicine. 1999; 3(6): 30.
26. Zhang GP, Jin HM, Zhang M, et al. Anticoagulative and fibrinolytic effects of lumbrokinase and their relation to tissue plasminogen activator. Chinese Journal of Geriatrics, 1998; 6(17): 366-368.
27. Zhang GP, Qian RZ, et al. Experimental observation of the inhibitory effects of lumbrokinase on platelets. National Medical Journal of China, 1998; 5(78): 394-95.
28. Zhang HY. Clinical evaluation of treating acute ischemic cerebrovascular disease with lumbrokinase. Capital Medicine, 2000; 7(3): 45-46.
29. Zhang JQ, Jing CH. Clinical evaluation of using Baiao lumbrokinase in the treatment of central retinal vein occlusion. Capital Medicine, 1999; 6(2): 51.
30. Zhang LP, et al. Preventative effects of lumbrokinase on experimentally induced emboli. Chinese Journal of Hemorheology, 1995, 11 (10): 679-680.
31. Zhang NH. Blood rheological changes of coronary artery disease patients prior and after lumbrokinase treatment. Chinese Journal of Hemorheology, 1999; 1(9): 63.
32. Zheng HJ, Xu JM, Huang ZH. Lumbrkinase capsule vs ticlopidine in treating coronary artery disease with angina pectoris. Chinese Journal of New Drugs and Clinical Remedies, 2000; 5(19): 406-408.
33. Zheng Z, Lin JN, et al. Observation of 20 unstable angina patients treated with Baiao lumbrokinase capsules. Capital Medicine, 2000; 7(6): 38.
34. Zhao J, Fan R, et al. Assay of lumbrokinase with a chromophoric substrate. Protein and Peptide Letters, 1997; 4(6): 409-14.
35. Zhou M, Wang FQ. The effects of lumbrokinase on blood rheology in patients with sudden hearing loss. Journal of Chinese Microcirculation, 2000; 3(4): 177-178.
36. Zhou XD, Zhao RX, Zheng XR, Zhang H. Observation of Boluoke (lumbrokinase) treatment in the recovery of motor function after cerebral infarction. Chinese Journal of Western and Chinese Medicine Cooperation, 1997; 12 (17).

Top of page